Medincell (XPAR:MEDCL) Other Long-Term Liabilities : €2.83 Mil (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Medincell Other Long-Term Liabilities?

Medincell's other long-term liabilities for the quarter that ended in Sep. 2023 was €2.83 Mil.

Medincell's quarterly other long-term liabilities increased from Sep. 2022 (€0.00 Mil) to Mar. 2023 (€0.00 Mil) and increased from Mar. 2023 (€0.00 Mil) to Sep. 2023 (€2.83 Mil).

Medincell's annual other long-term liabilities declined from Mar. 2021 (€0.86 Mil) to Mar. 2022 (€0.02 Mil) and declined from Mar. 2022 (€0.02 Mil) to Mar. 2023 (€0.00 Mil).

Medincell Other Long-Term Liabilities Historical Data

The historical data trend for Medincell's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Other Long-Term Liabilities Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Other Long-Term Liabilities	Get a 7-Day Free Trial										-	-	-	-	-

Medincell Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Medincell Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Medincell's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (XPAR:MEDCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines